DNDominik Nelic

Dominik Nelic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dominik Nelic has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Balancing Rigidity and Flexibility: Optimised 4-(Hexyloxy)benzoate Antagonists with Enhanced Affinity and Tuneable Duration at Muscarinic Receptors

    by Eva Dolejší, Eva Mezeiova, Jana Bláhová, Nikolai Chetverikov, Alena Janoušková-Randáková, Dominik Nelic, Lukas Prchal, Barbora Svobodova, John Boulos, Jan Korabecny, et al.

    Muscarinic acetylcholine receptors (mAChRs) regulate numerous physiological functions and represent established therapeutic targets for various central and peripheral disorders. This study investigates structural analogues of the long-acting muscarinic antagonist KH-5, focusing on the impact of modifications to the nitrogen-containing heterocycle on receptor binding, affinity, and duration of functional antagonism. A series of 4-(hexyloxy)benzoate derivatives and their N-methylated quaternary ammonium salts were synthesised, characterised, and tested for binding affinity at all five muscarinic receptor subtypes (M1–M5). Molecular docking and dynamics simulations revealed that stable hydrogen bonding to N6.52 and salt bridge formation with D3.32 were critical for ligand-receptor interactions. Experimental data indicated that compounds containing an azabicyclo[2.2.2]octan-1-ium group (e.g., 10a, 11a) exhibited the highest affinity and potency (up to 250-fold compared to lead compounds). However, these compounds had shorter functional antagonism half-lives compared to lead compounds, likely due to reduced molecular flexibility. Conversely, analogues retaining moderate flexibility (e.g., 7g) showed a balance between potency and sustained action. Structure- activity analysis demonstrated that charged nitrogen and the presence of a 4-hexyloxy substituent were critical for binding and prolonged activity. Shortening the alkoxy chain markedly decreased affinity and abolished long-term antagonism. Docking energies alone were insufficient to distinguish binders from non-binders; however, molecular dynamics-based metrics such as stable hydrogen bonding to N6.52 better predicted affinity. These findings emphasise the need for optimal spatial arrangement and charge distribution for high-affinity, long-residence muscarinic antagonists and provide a framework for future design of therapeutic agents targeting mAChRs. Highlights New analogues show up to 250× higher affinity at muscarinic receptors N6.52 H-bonding during MD predicts compound binding better than docking energies Charged nitrogen and 4-hexyloxy are key to high affinity and sustained action Rigid azabicyclo groups boost potency but shorten antagonism duration Flexible analogues balance potency with longer receptor residence time better

  • Evaluation of pharmacokinetics, pharmacodynamics, and toxicity of potential quinazoline bronchodilators derived from vasicinone

    by Marcel Špulák, Dominik Nelic, Alena Randáková, Klára Konečná, Ondřej Janďourek, Lucie Smutná, Vladimír Kubíček, Nicholas Gathergood, Jana Pourová, Petr Pávek, et al.

  • Open Access

    Cholesterol differentially modulates the activity of opioid and muscarinic receptors via a common binding site

    by Nikolai Chetverikov, Alena Janoušková-Randáková, Dominik Nelic, Jan Jakubík

    G protein-coupled receptors (GPCRs) are membrane proteins that represent the largest and most therapeutically targeted receptor class, accounting for 30% of currently marketed drugs. Two binding motifs for membrane cholesterol, the cholesterol recognition amino acid consensus (CRAC) domain and the cholesterol consensus motif (CCM), have been postulated. Using a simulation of the molecular dynamics of cholesterol association with the receptor, we predicted the binding of membrane cholesterol to non-canonical sites, distinct from CRAC and CCM, at muscarinic and opioid receptors. We identified a binding site common to muscarinic and opioid receptors at TM6, with arginine 6.35 as the major residue. Membrane cholesterol depletion mimics the effects of R 6.35 mutations, confirming its role in receptor modulation. Targeting cholesterol-binding sites offers novel pharmacotherapeutic strategies, including tissue-specific sterol-based modulation. One sentence summary: This study identifies a shared non-canonical cholesterol-binding site at TM6 in muscarinic and opioid receptors, with significant implications for drug development targeting tissue-specific GPCR modulation.